Skip to main content
Premium Trial:

Request an Annual Quote

'There in Places'

At What Matters, Rik Kirkland speaks with Esther Dyson, one of the Personal Genome Project 10 (totally different than the Oceanic Six) and a board member of 23andMe, about health, healthcare, and genetics. Dyson says that everything -- as exemplified by the Internet -- is turning into a "market of one." Though she says personalized medicine has begun, pointing to different treatments and prognoses for certain types of breast cancer, Dyson says the switchover isn't complete. "We're there in places, but we're very, very far from being there in general. This is something that people should want to do or volunteer to do, not something that should be imposed on them," she says, adding that she expects to see a change in how healthcare is delivered within the next five to 10 years.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.